Key result
Aspirin plus low-dose rivaroxaban cuts ischemic stroke ~51% versus aspirin alone despite similar major cardiovascular events across strategies.
Why the study?
Optimal antithrombotic therapy during the chronic maintenance period in patients with CAD is unknown.
Do different chronic maintenance antithrombotic strategies reduce MACE in patients with coronary artery disease at least one year after the acute phase?
Meta-Analysis (n=82,084)
Do different chronic maintenance antithrombotic strategies reduce MACE in patients with coronary artery disease at least one year after the acute phase?
Network meta-analysis suggests no significant difference in MACE among five chronic antithrombotic strategies for CAD, though aspirin plus low-dose rivaroxaban may reduce ischemic stroke and prolonged DAPT increases total bleeding compared to aspirin alone.
Answers are grounded in this paper and cite their sources.
Supports individualized antithrombotic selection given equivalent MACE risk; extends evidence for ischemic stroke reduction with aspirin plus low-dose rivaroxaban.
Background: Optimal antithrombotic therapy during the chronic maintenance period in patients with coronary artery disease (CAD) is unknown. We compared five kinds of mainstream chronic maintenance antithrombotic strategies at least one year after the acute phase: aspirin alone, clopidogrel alone, ticagrelor alone, continued dual antiplatelet therapy (DAPT) for a period of time, and maintenance with aspirin combined with a low-dose anticoagulant such as rivaroxaban. Methods: Ten randomized, controlled trials were selected using PubMed, Ovid MEDLINE, Embase, and Cochrane library through February 2023. The primary outcome was main adverse cardiac events (MACEs), and secondary outcomes include net adverse clinical events (NACEs), cardiac death, all-cause death, ischemic stroke, stent thrombosis, total bleeding, and major bleeding. A network meta-analysis was conducted with a random-effects model. Data extraction was performed by three independent reviewers. Results: Our search identified ten eligible randomized controlled trials enrolling a total of 82,084 patients comparing different chronic maintenance antithrombotic strategies. As for the primary endpoint, there was no statistical difference in MACE outcomes between any two of the five methods. As for the secondary endpoint, there was no statistical difference in NACE, major bleeding, all-cause death, cardiac death, and stent thrombosis between any two methods. The aspirin plus low-dose rivaroxaban group had a lower incidence of ischemic stroke compared to the aspirin group (OR = 0.49, 95% CrI 0.26-0.91). And the prolonged DAPT group had a higher total bleeding rate compared to aspirin group (OR = 2.4, 95% CrI 1.1-5.9). Conclusions: In terms of MACE, NACE, all-cause death, cardiac death, stent thrombosis, and major bleeding, there were no significant differences between using aspirin alone, clopidogrel alone, and ticagrelor alone; extending DAPT duration; and using aspirin combined with low-dose rivaroxaban for chronic maintenance antithrombotic regimens. However, choosing aspirin combined with low-dose rivaroxaban can reduce the incidence of ischemic stroke, and prolonged DAPT may have a higher rate of total bleeding. However, it is important to note that this study is based on indirect comparisons, and there is currently a lack of direct evidence comparing various maintenance antiplatelet therapy regimens. Further high-quality studies are needed to address this gap and provide more conclusive evidence on the comparative effectiveness of different maintenance antiplatelet strategies.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2023) conducted a meta-analysis in coronary artery disease (CAD) (n=82,084). Chronic maintenance antithrombotic strategies vs. Network comparison was evaluated on main adverse cardiac events (MACEs). Five chronic antithrombotic strategies showed no significant difference in major cardiovascular events, though aspirin plus low-dose rivaroxaban reduced ischemic stroke versus aspirin alone.
Synapse has enriched 10 related papers. Consider them for comparative context: